BB 21217

DB17373InvestigationalCell transplant therapies

BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as idecabtagene vicleucel (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to...

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 17
Curator reviewed
Code names: BB 21217

Resolves to

Targets

Q02223TNFRSF17

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with BB 21217, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account